BIOMAT Database Logo BIOMAT Database Logo

[Metabolic capacity of the liver in chronic alcoholic liver diseases]. 1981

H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008108 Liver Diseases, Alcoholic Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS. Alcoholic Liver Diseases,Alcoholic Liver Disease,Liver Disease, Alcoholic
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008658 Inactivation, Metabolic Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion. Detoxication, Drug, Metabolic,Drug Detoxication, Metabolic,Metabolic Detoxication, Drug,Detoxification, Drug, Metabolic,Metabolic Detoxification, Drug,Metabolic Drug Inactivation,Detoxication, Drug Metabolic,Detoxication, Metabolic Drug,Detoxification, Drug Metabolic,Drug Inactivation, Metabolic,Drug Metabolic Detoxication,Drug Metabolic Detoxification,Inactivation, Metabolic Drug,Metabolic Drug Detoxication,Metabolic Inactivation
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000983 Antipyrine An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29) Phenazone,Anodynin,Pyramidone

Related Publications

H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
[Metabolic abnormalities of trace elements in alcoholic liver diseases].
February 1997, Nihon rinsho. Japanese journal of clinical medicine,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
The bromosulphthalein loading test in chronic alcoholic liver diseases.
March 1984, Bollettino della Societa italiana di biologia sperimentale,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
[HLA antigens and chronic alcoholic liver diseases].
January 1988, Minerva dietologica e gastroenterologica,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
[Virus B infection in chronic alcoholic liver diseases].
October 1983, Recenti progressi in medicina,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
[Liver-protective action of silymarin therapy in chronic alcoholic liver diseases].
December 1989, Orvosi hetilap,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
[Decreased serum osteocalcin level in non-alcoholic and alcoholic chronic liver diseases].
June 1991, Orvosi hetilap,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
Aldehyde dehydrogenase (E.C. 1.2.1.3) in chronic alcoholic liver diseases.
August 1983, Hepato-gastroenterology,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
[Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].
June 1990, Orvosi hetilap,
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
Liver and pancreatic diseases: consequences of chronic alcoholic consumption.
January 2010, Digestive diseases (Basel, Switzerland),
H Adamska-Dyniewska, and S Biernat, and A Kulig, and A Szeszko, and W Tkaczewski
[Role of acute alcoholic and viral hepatites in evolution of chronic alcoholic liver diseases].
January 1982, Terapevticheskii arkhiv,
Copied contents to your clipboard!